Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
Ono Pharmaceutical plans to file its anti-PD-1 antibody Opdivo (nivolumab) in Japan for an additional indication of second-line esophageal cancer in January-March 2019, President Gyo Sagara revealed on November 1. Giving an update on the company’s pipeline in Japan, Mr…
To read the full story
Related Article
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…